elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38444096-B5731068-0FBB-429A-804D-3CDDB234FCD4
Q38444096-B5731068-0FBB-429A-804D-3CDDB234FCD4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38444096-B5731068-0FBB-429A-804D-3CDDB234FCD4
MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.
P2860
Q38444096-B5731068-0FBB-429A-804D-3CDDB234FCD4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38444096-B5731068-0FBB-429A-804D-3CDDB234FCD4
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
891309e5b6574d552749e2602def3f7a3418970b
P2860
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.